1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers
Clinical Efficacy of Subgingivally Delivered 1% Alendronate in the Treatment of Smokers With Chronic Periodontitis: a Randomized Placebo Controlled Clinical Trial.
- Locally delivered Alendronate (ALN) have potent inhibitory effect on bone and increases new bone formation in chronic periodontitis patients
- Till date no study has reported the effect of local delivery of ALN in chronic periodontitis patients among smokers. Hence the aim of this study is to investigate the clinical and radiographic effects of locally delivered ALN as an adjunct to the non surgical treatment in smoker chronic periodontitis patients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
- No history of periodontal therapy in preceding last 6 months
- No use of antibiotics in the preceding 6 months
Exclusion Criteria:
- Subjects with known systemic disease
- Known or suspected allergy to the ALN/bisphosphonate group
- Those on systemic ALN/bisphosphonate therapy
- Subjects with aggressive periodontitis,
- Use of smokeless tobacco in any form,
- Alcoholics
- Immunocompromised subjects
- Pregnant or lactating females
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Alendronate
1% Alendronate gel once in periodontal pocket (Gums)
|
|
|
Placebo Comparator: Placebo
Placebo gel once in periodontal pocket (Gums)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline plaque scores at 2 month and 6 month
Time Frame: At baseline, 2nd month and 6th month
|
Plaque scores assessed at baseline, at 2 months and 6 months for Alendronate and placebo group
|
At baseline, 2nd month and 6th month
|
|
Change from baseline gingival scores at 2 month and 6 month
Time Frame: At baseline, 2nd month and 6th month
|
Gingival scores assessed at baseline, at 2 months and 6 months for Alendronate and placebo group
|
At baseline, 2nd month and 6th month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline Probing depth at 2 month and 6 month
Time Frame: At baseline, 2nd month and 6th month
|
Probing depth assessed at baseline, at 2 months and 6 months for Alendronate and placebo group
|
At baseline, 2nd month and 6th month
|
|
Change from baseline Periodontal attachment level at 2 month and 6 month
Time Frame: At baseline, 2nd month and 6th month
|
Periodontal attachment level assessed at baseline, at 2 months and 6 months for Alendronate and placebo group
|
At baseline, 2nd month and 6th month
|
|
Change from baseline intrabony defect depth at 6 month
Time Frame: At baseline and 6th month
|
intrabony defect depth assessed at baseline and 6 months for Alendronate and placebo group
|
At baseline and 6th month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dr. Anuj Sharma, BDS, MDS, RIMS, Ranchi
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GDCRI-09-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Periodontitis
-
NCT07293962RecruitingPeriodontitis | Periodontitis Chronic Generalized Moderate | Periodontitis (Stage 3) | Periodontitis, Adult | Periodontitis Chronic Generalized Severe | Periodontitis, Chronic | Periodontitis Stage II | Periodontitis Chronic Localized Slight | Periodontitis Stage III
-
NCT03628872CompletedPeriodontal Diseases | Generalized Moderate Chronic Periodontitis | Generalized Severe Chronic Periodontitis
-
NCT07609888CompletedPeriodontitis | Chronic Periodontitis (Disorder)
-
NCT03262701TerminatedPeriodontitis, Chronic
-
NCT02283736Unknown-Chronic Periodontitis
-
NCT03083535Unknown
-
NCT03692819CompletedChronic Periodontitis Complex
-
NCT03783845CompletedChronic Periodontitis, Generalized
-
NCT02880397CompletedGeneralized Chronic Periodontitis
-
NCT05823389CompletedChronic Periodontitis, Generalized
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT06767540Not yet recruiting
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04693039Completed
-
NCT01610388Completed
-
NCT01550471CompletedAsthma | Allergic Rhinitis